Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.43 |
| ▸ | MTOR | P42345 | 12/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195965 | 0.82 | PIK3CA (0.44) | PIK3CAPIK3CDMTORPOLBATR | |
| SCHEMBL1271464 | 0.78 | MTOR (0.62) | PIK3CAPIK3CDMTORPOLBATR | |
| SCHEMBL2487135 | 0.76 | ATR (0.44) | PIK3CAMTORATRPRKDC | |
| SCHEMBL23848911 | 0.76 | PIK3CA (0.53) | PIK3CAPIK3CDMTORATR | |
| SCHEMBL4200787 | 0.70 | POLB (0.36) | PIK3CAPIK3CDMTORPOLBATR | |
| SCHEMBL3927579 | 0.70 | POLB (0.36) | PIK3CAPIK3CDMTORPOLBATR | |
| SCHEMBL23848909 | 0.69 | PIK3CA (0.51) | PIK3CAPIK3CDMTORATR | |
| SCHEMBL1272010 | 0.68 | POLB (0.42) | MTORPOLBCYP3A4 | |
| SCHEMBL1271969 | 0.68 | ALDH1A1 (0.37) | PIK3CAPIK3CDMTORPOLBCYP3A4 | |
| SCHEMBL3923572 | 0.68 | POLB (0.46) | PIK3CAPIK3CDMTORPOLBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379530-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ASTRAZENECA (SE) | 2011-03-03 | — | — | US | disclosed |
| WO-2010073034-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ABCG2, CYP3A7, CYP2C19 | PIK3CA 1564/4885PIK3CD 2358/4885MTOR 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.